Marc Frahm
Stock Analyst at TD Cowen
(0.10)
# 4,124
Out of 4,784 analysts
16
Total ratings
15.38%
Success rate
-33.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
SANA Sana Biotechnology | Upgrades: Buy | n/a | $1.71 | - | 2 | Jan 8, 2025 | |
TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $9.23 | -2.49% | 3 | Aug 6, 2024 | |
INCY Incyte | Maintains: Buy | $88 → $80 | $60.60 | +32.01% | 3 | May 1, 2024 | |
CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $8.02 | - | 1 | Jun 15, 2023 | |
XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.75 | - | 1 | Nov 16, 2021 | |
NUVL Nuvalent | Initiates: Outperform | n/a | $73.05 | - | 1 | Aug 23, 2021 | |
ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.26 | - | 1 | Jul 20, 2021 | |
JANX Janux Therapeutics | Initiates: Outperform | n/a | $29.10 | - | 1 | Jul 6, 2021 | |
DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $8.07 | - | 1 | Jun 21, 2021 | |
INZY Inozyme Pharma | Initiates: Outperform | n/a | $0.92 | - | 1 | Aug 18, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.61 | - | 1 | Feb 24, 2020 |
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $1.71
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.23
Upside: -2.49%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88 → $80
Current: $60.60
Upside: +32.01%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.02
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.75
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $73.05
Upside: -
Elevation Oncology
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.26
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $29.10
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.07
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.92
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.61
Upside: -